Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 33.35 -1.07% -0.36
PTLA closed down 1.07 percent on Wednesday, April 18, 2018, on 46 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Apr 18 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Apr 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Apr 18 Inside Day Range Contraction 0.00%
Apr 18 Upper Bollinger Band Touch Strength 0.00%
Apr 17 Wide Bands Range Expansion -1.07%
Apr 17 Above Upper BB Strength -1.07%
Apr 17 Upper Bollinger Band Touch Strength -1.07%
Apr 16 Shooting Star Candlestick Bearish 2.08%
Apr 16 Doji - Bearish? Reversal 2.08%
Apr 16 Wide Bands Range Expansion 2.08%

Older signals for PTLA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.1
52 Week Low 30.1
Average Volume 1,294,025
200-Day Moving Average 49.9077
50-Day Moving Average 37.5996
20-Day Moving Average 32.135
10-Day Moving Average 32.289
Average True Range 1.7179
ADX 34.48
+DI 21.08
-DI 25.24
Chandelier Exit (Long, 3 ATRs ) 29.6163
Chandelier Exit (Short, 3 ATRs ) 35.5237
Upper Bollinger Band 33.8268
Lower Bollinger Band 30.4432
Percent B (%b) 0.86
BandWidth 10.529329
MACD Line -1.202
MACD Signal Line -1.8305
MACD Histogram 0.6285
Fundamentals Value
Market Cap 1.92 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -7.33
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.90
Resistance 3 (R3) 34.91 34.41 34.64
Resistance 2 (R2) 34.41 34.02 34.40 34.55
Resistance 1 (R1) 33.88 33.77 33.63 33.87 34.47
Pivot Point 33.38 33.38 33.26 33.37 33.38
Support 1 (S1) 32.85 32.99 32.60 32.84 32.23
Support 2 (S2) 32.35 32.74 32.34 32.15
Support 3 (S3) 31.82 32.35 32.06
Support 4 (S4) 31.81